Therapeutic Target Details
| Target ID: | T37 |
| Target Name: | Caspase-2 |
| Synonyms: | Caspase-2; CASP-2 |
| GENE: | CASP2 |
| Action: | inhibitor |
| Class: | Enzyme |
| UniProtKB ID: | P42575 |
| Entry Name: | CASP2_HUMAN |
| Related Drugs: | None |
| Mechanism: | Caspase-2 inhibition offers a specific and effective strategy for preventing or treating stress-driven fatty liver diseases, whereas caspase-2-generated S1P proteolytic fragments, which enter the secretory pathway, are potential NASH biomarkers. |
| Reference (PMIDs): | 30220454 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|
| Compound ID | Source ID | Source Type | Compound Name | Molecular Weight | Molecular Formula | Molecular Species | |
|---|---|---|---|---|---|---|---|
| B002216 | CHEMBL1241268 | Small molecule | -- | 181.22 | C8H7NO2S | NEUTRAL | Details |
| B002217 | CHEMBL1241348 | Small molecule | FALDAPREVIR | 869.84 | C40H49BrN6O9S | ACID | Details |
| B021712 | CHEMBL1371684 | Small molecule | -- | 272.37 | C15H16N2OS | NEUTRAL | Details |
| B046263 | CHEMBL146453 | Small molecule | -- | 627.12 | C25H23ClN2O9S3 | ACID | Details |
| B049425 | CHEMBL147642 | Small molecule | -- | 456.45 | C17H16N2O9S2 | ACID | Details |
| B049795 | CHEMBL147775 | Small molecule | -- | 608.05 | C25H22ClN3O9S2 | ACID | Details |
| B050847 | CHEMBL148162 | Small molecule | -- | 641.15 | C26H25ClN2O9S3 | ACID | Details |
| B053903 | CHEMBL149307 | Small molecule | -- | 623.07 | C25H23ClN4O9S2 | ACID | Details |
| B059921 | CHEMBL1515648 | Small molecule | -- | 316.38 | C16H16N2O3S | NEUTRAL | Details |
| B095947 | CHEMBL179503 | Small molecule | -- | 598.15 | C27H44ClN7O6 | ACID | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A03302 | 34052187 | Biochem Pharmacol | Upregulation of miR-96-5p by bone marrow mesenchymal stem cells and their exosomes alleviate non-alcoholic steatohepatitis: Emphasis on caspase-2 signaling inhibition. | Details |
| A12932 | 30220454 | Cell | ER Stress Drives Lipogenesis and Steatohepatitis via Caspase-2 Activation of S1P. | Details |
| A17199 | 27917437 | Cell Tissue Res | Nicotine plus a high-fat diet triggers cardiomyocyte apoptosis. | Details |
| A18875 | 26890135 | Cell Death Dis | Caspase-2 promotes obesity, the metabolic syndrome and nonalcoholic fatty liver disease. | Details |
| A19339 | 26621219 | Sci Rep | Inhibition of NF-κB by deoxycholic acid induces miR-21/PDCD4-dependent hepatocellular apoptosis. | Details |
| A19705 | 26403427 | Dig Dis Sci | Vitamin B5 and N-Acetylcysteine in Nonalcoholic Steatohepatitis: A Preclinical Study in a Dietary Mouse Model. | Details |
| A21774 | 25053716 | Gut | Reduced lipoapoptosis, hedgehog pathway activation and fibrosis in caspase-2 deficient mice with non-alcoholic steatohepatitis. | Details |
| A23704 | 23553630 | J Biol Chem | Metabolomic profiling reveals a role for caspase-2 in lipoapoptosis. | Details |
| A25788 | 21455726 | Diabetologia | Apoptosis and insulin resistance in liver and peripheral tissues of morbidly obese patients is associated with different stages of non-alcoholic fatty liver disease. | Details |
| A29903 | 33296631 | Med Sci (Paris) | [Caspase inhibition: From cellular biology and thanatology to potential clinical agents]. | Details |
| A47210 | 22841474 | Am J Pathol | Epigenetic regulation of miR-34a expression in alcoholic liver injury. | Details |